Multiple myeloma and the potential of new checkpoint inhibitors for immunotherapy

• Auteurs principaux: Ali N. Kamali (Auteur), Haleh Hamedifar (Auteur), Michael Eisenhut (Auteur), Jose M. Bautista (Auteur)
• Format: Livre
• Publié: SAGE Publishing, 2024-10-01T00:00:00Z.
• Sujets: article
• Accès en ligne: Connect to this object online.

Multiple myeloma (MM), a cancer of the bone marrow, is categorized as the second most common hematological malignancy of adults in the Western world. Despite dramatic improvements in immunotherapies in the field of cancers, MM immunotherapy has not been promising until now. Recent clinical studies o...